0001062993-24-003168.txt : 20240214 0001062993-24-003168.hdr.sgml : 20240214 20240214161442 ACCESSION NUMBER: 0001062993-24-003168 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240212 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith Thomas B CENTRAL INDEX KEY: 0001748462 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 24638339 MAIL ADDRESS: STREET 1: BIODELIVERY SCIENCES INTERNATIONAL, INC. STREET 2: 4131 PARKLAKE AVE SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-02-12 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001748462 Smith Thomas B C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 0 1 0 0 EVP and Chief Medical Officer 0 Common Stock 2024-02-12 4 A 0 30800 0 A 62980 D Common Stock 2024-02-12 4 A 0 4623 0 A 67603 D Common Stock 2024-02-12 4 F 0 1899 33.70 D 65704 D Common Stock 2024-02-12 4 F 0 1300 33.70 D 64404 D Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Includes 442 and 553 shares acquired on each of July 21, 2023 and January 19, 2024, respectively, under the Issuer's employee stock purchase plan. Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 4,623 performance share units ("PSUs") granted in the Issuer's prior fiscal year. Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. /s/ Colleen Tupper as Attorney-In-Fact For Thomas B. Smith, MD 2024-02-14